产品详细信息
- 与阶段相适应的严格质量体系包括 cGMP 标准和质量源于设计方法
- 与质谱兼容的高分辨率杂质分析方法有助于确保您的 CRISPR 分子具有高纯度
- 位于科罗拉多州的两个 cGMP 工厂可生产多种产品，并为多个项目提供支持，帮助您无缝转入生产阶段
- 由拥有 20 年以上经验的科学家组成的专家团队，为多个临床和商业项目的开发提供支持
- 与经验丰富的伙伴合作，帮助您获得长期成功
- 项目经理协调跨职能团队，以明确了解您的要求并确保项目成功完成
- 重要资料
-
Agilent ClinGuide CRISPR sgRNA for Human Therapeutics
Accelerate the clinical success of therapeutic gene editing programs.
- 宣传单页
- English
- 2023 年 10 月 12 日
- 1.12 MB
Accelerate Your Journey from Clinic to Market
Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs
- 产品样本
- English
- 2023 年 12 月 28 日
- 3.19 MB
视频
Agilent to Acquire North American CDMO BIOVECTRA
Agilent Technologies signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. This expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing.
- Agilent to Acquire North American CDMO BIOVECTRA
- 2024 年 7 月 22 日
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.
- 2022 年 12 月 5 日